S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for
tumor cell growth.
PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with
unresectable or metastatic malignant peripheral nerve sheath tumor.